title: Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
abstract: OBJECTIVE
  The aims of the present study were to (1) assess clinical features and long-term outcome in anti-Jo1-positive patients with anti-Ro52 antibody; (2) compare characteristics of anti-Jo1-positive patients with and without anti-Ro52 antibody; and (3) compare features of anti-Ro52-positive patients with and without anti-Jo1 antibody.
  
  
  METHODS
  The medical records of 89 consecutive anti-Jo1-positive patients with antisynthetase syndrome (ASS) were reviewed; 36 of these patients had coexistent anti-Ro52 antibody. Furthermore, the medical records of 13 consecutive anti-Ro52-positive patients without anti-Jo1 antibody were also reviewed.
  
  
  RESULTS
  Nine anti-Jo1-positive patients (25%) with anti-Ro-52 antibody achieved remission of ASS, whereas 19 other patients (52.8%) improved and 8 patients (22.2%) worsened their clinical status. Anti-Jo1-positive patients with anti-Ro52 antibody experienced ASS-related complications: interstitial lung disease (n = 28), esophageal dysfunction (n = 9), and joint manifestations (n = 25), including periarticular hydroxyapatite calcifications and erosions of metacarpophalangeal and interphalangeal joints and wrists (n = 3); 7 anti-Ro52-positive patients (19.4%) had cancer. Anti-Jo1-positive patients with anti-Ro52 antibody, compared with those without, more commonly experienced deterioration of myositis and joint involvement, symptomatic form of ILD, and cancer; they also had decreased survival rate (P = 0.05). We further found that anti-Ro52-positive patients with anti-Jo1 antibody, compared with those without, were younger and more frequently exhibited ILD with poorer prognosis.
  
  
  CONCLUSIONS
  Our series underlines that the presence of anti-Ro52 antibody is associated with a particular phenotype of ASS, leading to more severe myositis and joint impairment. Moreover, the coexistence of anti-Ro52 antibody seems to be associated with an increased risk of cancer. We therefore suggest that anti-Jo1-positive patients should routinely undergo the search for anti-Ro52 antibody, as this autoantibody appears to impact patients' prognosis.
authors.affiliation: Department of Internal Medicine, CHU Rouen, and INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France. isabelle.marie@chu-rouen.fr
authors.forename: Isabelle
authors.initials: I
authors.lastname: Marie
authors.forename: Pierre Yves
authors.initials: PY
authors.lastname: Hatron
authors.forename: Stéphane
authors.initials: S
authors.lastname: Dominique
authors.forename: Patrick
authors.initials: P
authors.lastname: Cherin
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Menard
authors.forename: Hervé
authors.initials: H
authors.lastname: Levesque
authors.forename: Fabienne
authors.initials: F
authors.lastname: Jouen
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D005260:Female; D006643:Histidine-tRNA Ligase / Q000276:immunology*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000097:blood / Q000150:complications / Q000276:immunology; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000097:blood / Q000276:immunology; D009220:Myositis / Q000097:blood / Q000150:complications / Q000276:immunology*; D011379:Prognosis; D012189:Retrospective Studies; D012261:Ribonucleoproteins / Q000276:immunology*; D000099207:SS-A Antigen
chemical_list: D001323:Autoantibodies; D006643:Histidine-tRNA Ligase; D012261:Ribonucleoproteins; D000099207:SS-A Antigen